Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4099-4109

  Capolla, Sara ^a   Garrovo, Chiara ^b   Zorzet, Sonia ^a   Lorenzon, Andrea ^c   Rampazzo, Enrico ^d   Spretz, Ruben ^e   Pozzato, Gabriele ^a   Núñez, Luis ^f   Tripodo, Claudio ^g   Macor, Paolo ^a,h   Biffi, Stefania ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c Animal Care Unit   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e LNKChemsolutions   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF PALERMO   (Italy)

^h Callerio Foundation   (Italy)

Author keywords

Active targeting; Optical imaging; Tumor accumulation

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIBODY NANOPARTICLE CONJUGATE; CD20 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; DYE; NANOPARTICLE; UNCLASSIFIED DRUG; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER DIAGNOSIS; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEC1 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; WHOLE BODY IMAGING; ANIMAL; CHEMISTRY; LEUKEMIA, B-CELL; MOLECULAR IMAGING; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD20; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, B-CELL; MICE; MOLECULAR IMAGING; NANOPARTICLES; POLYMERS;

EID: 84933524531     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S78995     Document Type: Article

References (33)

1. Dawidczyk CM, Kim C, Park JH, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nano-medicines. J Control Release. 2014;187:133–144.
2. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653–664.
3. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104:15549–15554.
4. Chattopadhyay N, Fonge H, Cai Z, et al. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm. 2012;9(8):2168–2179.
5. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014;9:467–483.
6. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759–768.
7. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740.
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
9. Gu G, Xia H, Hu Q, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34:196–208.
10. Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:2534.
11. Valencia PM, Pridgen EM, Rhee M, Langer R, Farokhzad OC, Karnik R. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano. 2013;7:10671–10680.
12. Pirollo KF, Chang EH. Does a targeting ligand infuence nanoparticle tumor localization or uptake? Trends Biotechnol. 2008;26:552–558.
13. Theek B, Gremse F, Kunjachan S, et al. Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. J Control Release. 2014;182:83–89.
14. Kunjachan S, Pola R, Gremse F, et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett. 2014;14:972–981.
15. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
16. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 2008;1:17–32.
17. Mezzaroba N, Zorzet S, Secco E, et al. New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/ hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One. 2013; 8(9):e74216.
18. Marín GH, Mansilla E, Mezzaroba N, et al. Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. Curr Clin Pharmacol. 2010;5:246–250.
19. Rampazzo E, Boschi F, Bonacchi S, et al. Multicolor core/shell silica nanoparticles for in vivo and ex vivo imaging. Nanoscale. 2012;4: 824–830.
20. Macor P, Secco E, Mezzaroba N, et al. Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia. 2015;29(2):406–414.
21. Zabucchi G, Soranzo MR, Menegazzi R, et al. Eosinophil peroxidase deficiency: morphological and immunocytochemical studies of the eosinophil-specific granules. Blood. 1992;80:2903–2910.
22. Biff S, Dal Monego S, Dullin C, et al. Dendritic polyglycerolsulfate near infrared fuorescent (NIRF) dye conjugate for non-invasively monitoring of infammation in an allergic asthma mouse model. PLoS One. 2013;8:e57150.
23. Biff S, Petrizza L, Rampazzo E, et al. Multiple dye-doped NIR-emitting silica nanoparticles for both fow cytometry and in vivo imaging. RSC Adv. 2014;4:18278–18285.
24. Biff S, Garrovo C, Macor P, et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging. 2008;7:272–282.
25. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911–919.
26. Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolym-phocytoid transformation. Leuk Res. 1999;23:127–136.
27. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
28. Bertilaccio MT, Scielzo C, Simonetti G, et al. A novel Rag2-/-gammac-/--xenograft model of human CLL. Blood. 2010;115:1605–1609.
29. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869–877.
30. Bancroft GJ, Kelly JP. Macrophage activation and innate resistance to infection in SCID mice. Immunobiology. 1994;191:424–431.
31. Mansilla E, Marin GH, Nuñez L, et al. The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro. Cancer Biother Radiopharm. 2010;25:97–103.
32. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–689.
33. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111(2):865–873.